Viz.ai Adds Cortechs.ai's NeuroQuant MS To Care Coordination Platform
Viz.ai will embed Cortechs.ai's NeuroQuant MS quantitative MRI analysis inside its care coordination platform, extending Viz Neuro Suite into neurodegenerative disease.
Key Takeaways
Viz.ai will embed Cortechs.ai's NeuroQuant MS quantitative MRI analysis suite directly into its care coordination platform, per a deal announced July 9, 2026.
The integration extends Viz Neuro Suite beyond stroke and acute neurological events into neurodegenerative disease, with more neurodegenerative products and partnerships promised.
NeuroQuant MS converts routine MRI scans into quantitative measures of multiple sclerosis lesion burden and brain-volume change over time, accessible within Viz.ai's imaging worklist and radiology-neurology workflow.
The integration will run across the nearly 2,000 U.S. hospitals on Viz.ai's platform.
Cortechs.ai brings a portfolio of FDA-cleared quantitative brain MRI tools spanning dementia and MS, bolstered by its recent acquisition of ZepMed's neuroimaging technology.
Kaan Tınmaz
San Francisco, July 9, 2026 — Viz.ai and Cortechs.ai have inked an integration deal that will drop Cortechs.ai's NeuroQuant MS quantitative MRI analysis suite inside Viz.ai's care coordination platform. The move extends Viz.ai's Viz Neuro Suite beyond stroke and other acute neurological events into neurodegenerative disease — a strategic expansion Viz.ai says will be followed by additional neurodegenerative product and partnership announcements.
Quantitative MRI, Inside The Workflow
NeuroQuant MS turns routine MRI scans into quantitative measurements of multiple sclerosis lesion burden and brain-volume change over time. Once embedded in Viz.ai's coordination workflow, clinicians will be able to access those measurements alongside the imaging worklist and radiology-neurology conversation that Viz.ai already choreographs, without leaving the platform. Viz.ai says the integration will run across the nearly 2,000 U.S. hospitals now on its platform.
Expanding Viz Neuro Suite
Viz.ai has spent 2026 broadening beyond its stroke roots. Its pulmonary AI suite launched earlier this year, and this month's Cortechs.ai deal is aimed at neurodegenerative workflow. Cortechs.ai — whose recent acquisitions include ZepMed's neuroimaging technology — brings a portfolio of FDA-cleared quantitative brain MRI tools that spans dementia and MS.
A Busy AI-Imaging Week
The tie-up ships alongside a broader wave of AI-imaging news, including UpDoc's first patient-facing clinical LLM FDA clearance and Philips' new AI research partnership with the University of Washington on non-contrast breast MRI. Viz.ai and Cortechs.ai said further neurodegenerative disease integrations are due in coming months.
Reporting based on Viz.ai and Cortechs.ai company statements and coverage from AuntMinnie.
NeuroQuant MS analyzes routine MRI scans to produce quantitative measurements of multiple sclerosis lesion burden and brain-volume change over time, which clinicians can now access inside Viz.ai's care coordination workflow without leaving the platform.
How many hospitals will get the Viz.ai–Cortechs.ai integration?
Viz.ai says the NeuroQuant MS integration will run across the nearly 2,000 U.S. hospitals currently on its care coordination platform.
Why is this deal significant for Viz.ai?
It extends the Viz Neuro Suite beyond its stroke and acute neurological roots into neurodegenerative disease, part of a 2026 expansion that also included a pulmonary AI suite, with further neurodegenerative integrations expected in coming months.
What does Cortechs.ai bring to the partnership?
Cortechs.ai offers a portfolio of FDA-cleared quantitative brain MRI tools covering dementia and MS, and recently acquired ZepMed's neuroimaging technology.
